

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/006,591	12/05/2001	Katherine S. Bowdish	ALEX-P01-055	3521
28120 FISH & NEAV	7590 04/25/2007 /F. IP GROUP	EXAMINER		
ROPES & GR	AY LLP		SCHLAPKOHL, WALTER	
ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624			ART UNIT	PAPER NUMBER
,,			1636	
	•		MAIL DATE	DELIVERY MODE
			04/25/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	Applicant(s)		
10/006,591	BOWDISH ET AL.			
Examiner	Art Unit			
Walter Schlapkohl	1636	auf		

		Vvalter Ochlapkom	1030		
	The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence add	ress	
THE F	REPLY FILED <u>02 April 2007</u> FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR A	LLOWANCE.		
† 	The reply was filed after a final rejection, but prior to or or chis application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Notal Request for Continued Examination (RCE) in compliant time periods:	wing replies: (1) an amendment, a otice of Appeal (with appeal fee) in ce with 37 CFR 1.114. The reply n	ffidavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)	
- a)	\boxtimes The period for reply expires $\underline{3}$ months from the mailing date	e of the final rejection.			
b)	The period for reply expires on: (1) the mailing date of this A				n
	no event, however, will the statutory period for reply expire		•		
	Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	706.07(f).			
have b under i set fort may re	ions of time may be obtained under 37 CFR 1.136(a). The date een filed is the date for purposes of determining the period of ex 37 CFR 1.17(a) is calculated from: (1) the expiration date of the h in (b) above, if checked. Any reply received by the Office late duce any earned patent term adjustment. See 37 CFR 1.704(b) CE OF APPEAL	ctension and the corresponding amoun shortened statutory period for reply ori or than three months after the mailing d	t of the fee. The appropr ginally set in the final Offi	iate extension fee ice action; or (2) a	as
2.	The Notice of Appeal was filed on A brief in comp	pliance with 37 CFR 41.37 must be	e filed within two month	ns of the date of	f
;	filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed IDMENTS	ension thereof (37 CFR 41.37(e)),	to avoid dismissal of th	e appeal. Since	•
	The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brie	f will not be entered b	ocalise	
0.	(a) \boxtimes They raise new issues that would require further co	onsideration and/or search (see N	TF below):	ccause	
	(b) They raise the issue of new matter (see NOTE belo	ow);	, , <u>, , , , , , , , , , , , , , , , , </u>		
	(c) They are not deemed to place the application in be appeal; and/or	The state of the s	educing or simplifying	the issues for	
	(d) They present additional claims without canceling a	corresponding number of finally re	ejected claims.		
	NOTE: See Continuation Sheet. (See 37 CFR 1.1	116 and 41.33(a)).			
4.			ompliant Amendment	(PTOL-324).	
5. 🔲	Applicant's reply has overcome the following rejection(s)) :			
6. 🔲	Newly proposed or amended claim(s) would be a	llowable if submitted in a separate	, timely filed amendme	ent canceling the	е
	non-allowable claim(s).				
	For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		ill be entered and an e	explanation of	
	Claim(s) objected to:				
	Claim(s) rejected: <u>1-6,23,24,26-37,73,74 and 85-104</u> .				
	Claim(s) withdrawn from consideration: DAVIT OR OTHER EVIDENCE				
8. 🗌	The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good arwas not earlier presented. See 37 CFR 1.116(e).				d
9. 🔲	The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessal	overcome all rejections under app	eal and/or appellant fa	ils to provide a	
	The affidavit or other evidence is entered. An explanation	- ·		•	
	JEST FOR RECONSIDERATION/OTHER	on or the status of the stating after	citify to below of attack	ilou.	
	The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application	in condition for allowa	nce because:	
	Note the attached Information Disclosure Statement(s). Other:	(PTO/SB/08) Paper No(s).	David o	luzo	ugo.
			en sette til etter Historia fra Cadal Call		

Continuation Sheet (PTO-303)

Continuation of 3. NOTE: Applicant's amendment introduces a limitation into the claims which was not previously presented. Specifically, Applicant has amended claims 1, 23, 33-36, 85 and 92 to recite "anneals specifically" in place of "are capable of annealing," "is capable of annealing," or "being capable of annealing." Furthermore, Applicant's amendment introduces a limitation into claim 1 with regard to the 20 nucleotides which separate the primer and collar sequences; this limitation was not previously presented. Because Applicant's amendment introduces new limitations into the claims, the amendment raises new issues with regard to search and consideration. Moreover, Applicant has introduced a limitation into claim 1 which specifies that the primer and collar sequences of the claimed plasmid do not specifically anneal to the at least 20 nucleotides which separate the portions of the polypeptide encoding sequence to which they anneal. This amendment raises the issue of new matter because the specification does not appear to provide sufficient blazemarks nor direction for the instant limitation as claimed.

Continuation of 11. does NOT place the application in condition for allowance because: The amendment of the claims to recite "anneals specifically" in place of "are capable of annealing," "is capable of annealing," or "being capable of annealing" is not sufficient to overcome the rejection of the claims under 35 U.S.C. 112, 2nd paragraph, as vague and indefinite. The specification does not provide sufficient guidance with regard to the extent or nature of sequences which anneal "specifically." For example, does Applicant intend primer and/or collar sequences in which 50% of the nucleotides in said sequence are complementary upon annealing, and therefore that there is "correct base pairing" (see page 9, bottom, of the Remarks filed 4.2.2007); or does Applicant intend only sequences which are 100% complementary upon annealing? Furthermore, while Applicant argues that one of skill in the art understands that "specifically" means there is correct base pairing (ibid), Examiner disagrees. Indeed, one of skill in the art would understand that specific annealing can take place under various conditions, some of which require greater accuracy with regard to base pairing than others, i.e., levels of higher or lower stingency.

With regard to the rejection of claims under 35 U.S.C. 112, first paragraph (new matter) of record. Applicant's arguments are not found persuasive because Applicant's arguments rely upon portions of the specification which provide support only for primers which range "from about 10 nucleotides to about 50 or more nucleotides in length"; there is no support for a range of "at least 10 nucleotides." Furthermore, Applicant's arguments with regard to the rejection of the claims under 35 U.S.C. 112, first paragraph, written description are found unpersuasive because amendment of the claims to recite primer and collar sequence which "specifically" anneal during a polymerase reaction to a first and second portion of a polypeptide encoding portion of a nucleic acid does not narrow the genus of encompassed plasmids enough to show that Applicant was in possesion of the claimed invention. Arguments drawn to a strong presumption that a specification as filed provides adequate written description support for the claimed invention and that "rejection of an original claim for lack of written description should be rare" do not address the deficiences in the specification or the prior art which Examiner has set forth in the Office action mailed 4/18/2006. Furthermore, Applicant's assertion that rejection of an original claim for lack of written description should be rare is found unpersuasive because the claims currently rejected under 35 U.S.C. 112, first paragraph, are not original claims. While Examiner agrees with Applicant insofar as the level of skill in the art with regard to plasmid construction and targeting is high, this argument also fails to address the deficiencies in the specification and the prior art as set forth in the Office action mailed 4/18/2006. Exemplification of primer and collar sequences which anneal to different portions of antibody-encoding sequences, in light of the other factors pertinent to the rejection (disclosure of a complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation and/or any combination thereof), does not reasonably convey to one skilled in the relevant art that Applicant had possesion of the claimed genus of plasmids.